2008
Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative
Carter CS, Barch DM, Buchanan RW, Bullmore E, Krystal JH, Cohen J, Geyer M, Green M, Nuechterlein KH, Robbins T, Silverstein S, Smith EE, Strauss M, Wykes T, Heinssen R. Identifying Cognitive Mechanisms Targeted for Treatment Development in Schizophrenia: An Overview of the First Meeting of the Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia Initiative. Biological Psychiatry 2008, 64: 4-10. PMID: 18466880, PMCID: PMC2577821, DOI: 10.1016/j.biopsych.2008.03.020.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsAntipsychotic AgentsBiomedical ResearchBrainCognition DisordersCooperative BehaviorDrug IndustryHumansNational Institute of Mental Health (U.S.)Neuropsychological TestsResearch Support as TopicSchizophreniaSchizophrenic PsychologyUnited StatesUnited States Food and Drug AdministrationConceptsCognitive Neuroscience Treatment ResearchSchizophrenia (MATRICS) initiativeTreatment researchCognitive neuroscience fieldCNTRICS initiativeCognitive mechanismsCognitive constructsTreatment developmentNeuroscience fieldCognitive impairmentCognitionBasic animalSchizophreniaResearchFirst meetingImpairmentConstructsParadigmTranslational researchTranslation effortsNovel treatmentsOrganization
1999
Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion
Bunney W, Azarnoff D, Brown B, Cancro R, Gibbons R, Gillin J, Hullett S, Killam K, Kupfer D, Krystal J, Stolley P, French G, Pope A. Report of the Institute of Medicine Committee on the Efficacy and Safety of Halcion. JAMA Psychiatry 1999, 56: 349-352. PMID: 10197830, DOI: 10.1001/archpsyc.56.4.349.Peer-Reviewed Original ResearchAdverse Drug Reaction Reporting SystemsChronic DiseaseDrug ApprovalDrug EvaluationEvaluation Studies as TopicHumansHypnotics and SedativesNational Academies of Science, Engineering, and Medicine, U.S., Health and Medicine DivisionPrevalenceProduct Surveillance, PostmarketingProfessional Staff CommitteesRandomized Controlled Trials as TopicResearch DesignSleep Initiation and Maintenance DisordersTriazolamUnited StatesUnited States Food and Drug Administration